Overview

Eltrombopag is most valuable in immune thrombocytopenia (ITP) when paired with other modalities rather than used alone, which is why combination strategy defines its clinical role. ELBONIX offers eltrombopag 25 mg and 50 mg film-coated tablets in 28-tablet boxes, enabling flexible dose titration. This article examines how the oral thrombopoietin-receptor agonist is combined with immunosuppression or used before procedures to raise platelet counts. Understanding these pairings helps buyers stock the right strengths for mixed patient needs.

How It Works

Eltrombopag is a small-molecule thrombopoietin receptor agonist that binds the transmembrane domain of TPO-R, stimulating megakaryocyte proliferation and platelet production in the bone marrow. Unlike infused thrombopoietin, it is orally active and has a distinct binding site. In combination practice, it raises the platelet floor while concomitant immunosuppression addresses the autoimmune drive behind ITP. The two mechanisms act in parallel, often allowing lower corticosteroid exposure than steroid monotherapy.

Indications

Eltrombopag is indicated for chronic ITP in adults and children who are refractory to other treatments, and for thrombocytopenia in hepatitis C or severe aplastic anaemia contexts per labelling. In combination, it is used to achieve platelet levels sufficient for surgery or to spare steroids. The availability of 25 mg and 50 mg strengths supports stepwise up-titration under monitoring.

Dosage & Administration

For ITP, eltrombopag is started at 25 mg or 50 mg once daily depending on whether the patient is of East Asian ancestry or taking interacting drugs, then adjusted by 25 mg at weekly intervals to a maximum of 75 mg. Tablets are taken on an empty stomach, at least two hours from calcium-rich foods, dairy, antacids, or iron. A 28-tablet box covers one month at a fixed dose.

Storage & Sourcing

Store below 30°C in the original blister, protected from light and moisture. Eltrombopag is prescription-only; B2B supply needs licensed sourcing and market authorisation. Because the 25 mg and 50 mg packs are often used together during titration, buyers should forecast both strengths. Confirm batch expiry and certificate of analysis on arrival, and keep inventory aligned with monitored, individually dosed patient cohorts.

FAQ

Q: How is eltrombopag combined with immunosuppression in ITP? A: It is added to raise platelet counts while steroids or other immunosuppressants address the autoimmune cause, frequently permitting lower steroid doses.

Q: Why are both 25 mg and 50 mg strengths stocked? A: Starting and titration doses differ by patient factors, so having both packs lets clinics step the dose without switching suppliers mid-treatment.

Q: What dietary rule affects eltrombopag dosing? A: Calcium-rich foods, dairy, antacids, and iron bind the drug; doses are taken on an empty stomach, separated by at least two hours.